Exclusive Summary

• Proven Market Potential: As a highly similar biosimilar to the originator Lucentis (ranibizumab), UB674 taps into the massive and expanding ophthalmic anti-VEGF market, which saw peak originator sales of $5.56 billion.
• Advanced Regulatory Status: BLA has already been submitted in China. Extensive CMC, nonclinical, and clinical studies have demonstrated high similarity to Lucentis, allowing approval for all originator indications without the need for indication-by-indication clinical trials.
• Distinct Manufacturing Cost Advantages: Utilizes an innovative and scalable E. coli secretory expression system that ensures high yield and short production cycles. This grants a highly competitive cost structure and flexible pricing power.
• High Value for Out-Licensing & Tech Transfer: With a fully optimized commercial-scale manufacturing process, UB674 is ready for smooth technology transfer, making it an ideal asset for overseas pharmaceutical companies seeking cost-effective biologics to capture shares in global emerging markets.

Asset Materials

Contact Us for Full Materials